EKF Diagnostics Investor Announcements

EKF Diagnostics announces that its Quo-Test analyser has received US Food and Drug Administration 510(k) clearance for professional use in a clinical laboratory setting.

EKF announces the full launch of the McKesson Consult^® Hb analyzer in the US  in February.

EKF Diagnostics provides shareholders with the following update on current trading. 

EKF Diagnostics Holdings plc announces that, further to the announcement on 1 November regarding its planned appointment of a new nominated adviser following the admission of Renalytix AI PLC (“RenalytixAI”) to trading on AIM, the boards of EKF and RenalytixAI have now agreed a different resolution to the requirement for one of the two companies to appoint a new nominated adviser. 

EKF Diagnostics announces that on 19 December 2018, the Company was notified by Mike Salter (President, Americas) that he has today purchased 125,000 ordinary shares.

EKF Diagnostics announces an update in relation to its previously announced Buy-Back.

The Company's total issued share capital consists of 455,163,766 ordinary shares of 1 pence each with one voting right per share.

EKF Diagnostics announces an update to its prior announcement on 14 November 2018 in relation to the Buy-Back.

The Company confirms that on 20 November 2018, it purchased 1,641,493 of its ordinary shares on the London Stock Exchange at a price of 27.4348 pence per share. The purchased shares will be cancelled.

The Company confirms that on 19 November 2018, it purchased 178,423 of its ordinary shares on the London Stock Exchange at a price of 26.15 pence per share. The purchased shares will be cancelled.